Autologous haematopoietic SCT (HSCT) is now a standard treatment for a variety of relapsed or refractory haematological malignancies. Engraftment following HSCT is dependent upon the number and viability of stem cells in the graft. 1, 2 The degree of neutrophil contamination in haematopoietic progenitor cellapheresis (HPC-A) products has been inversely correlated to post-thaw nucleated cell recovery. 3 However, the correlation between haematopoietic recovery in autologous transplant recipients and the degree of neutrophil contamination in HPC-A has not been analysed. Therefore, we assessed the data from 446 consecutive patients who underwent autologous transplantation at our centre using HPC-A between 2001 and 2012. Correlation between the infused dose of neutrophils and the times to neutrophil and platelet engraftment was analysed using Pearson's correlation analysis. Other factors including age, gender, disease, infused CD34 þ cell dose and disease status at the time of transplantation were also studied to assess potential impacts on engraftment.
Increasing neutrophil contamination of HPC-A was strongly associated with slower neutrophil recovery (R 2 ¼ 0.035, Po0.005). By univariate analysis, infused neutrophil dose together with disease, and disease status (CR or not) at the time of transplantation were the factors that had an impact on neutrophil engraftment. Infused neutrophils X4 Â 10 8 /kg vs o4 Â 10 8 /kg resulted in longer times to neutrophil engraftment-12 (9-29) days vs 11 (8-28) days (Po0.005). There was a small but significant delay in neutrophil recovery associated with disease: transplantation for leukaemia or multiple myeloma resulted in a longer time to neutrophil engraftment when compared with a diagnosis of lymphoma (P ¼ 0.003). Factors affecting platelet engraftment were gender, disease, infused and post-thaw viable CD34 þ cell dose. Age at the time of transplantation did not have a significant impact on engraftment on univariate analysis.
On multivariate analysis, only infused neutrophil dose, gender and disease status remained significant for neutrophil recovery, whereas infused viable CD34 þ cell dose remained significant for platelet recovery. The number of infused neutrophils, o4 Â 10 8 /kg vs X4 Â 10 8 /kg, had no impact on graft failure rates (2.4% vs 0.9%, P ¼ 0.459); inpatient length of stay (15 (1-52) days vs 17 (9-62) days, P ¼ 0.066) or TRM (2.7% vs 5.2%, P ¼ 0.138).
To our knowledge, our study is the first to demonstrate a significant correlation between infused HPC-A neutrophil dose and time to neutrophil recovery post autologous transplantation. We confirm the negative impact of increasing neutrophil contamination of HPC-A and time to neutrophil engraftment, and show that this appears to be independent of total or post-thaw viable CD34 þ cell dose. This effect may be due to the lower tolerance of granulocytes to dimethyl sulfoxide when compared with other progenitor populations or lymphocytes in HPC-A products, as has been suggested by a previous study. 4 We also confirm a significant correlation between the number of post-thaw viable CD34 þ cells infused per kg body weight and platelet engraftment, but not neutrophil engraftment. Our findings are supported by other studies, 5, 6 suggesting that markers other than CD34 may be required to identify early progenitor populations that more accurately predict time to neutrophil engraftment. [6] [7] [8] [9] Efforts to reduce neutrophil contamination of apheresis products may improve neutrophil recovery following autologous transplantation. 
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